Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. ResApp Health Limited
  6. News
  7. Summary
    RAP   AU000000RAP5


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ResApp Health : Medgate extends European ResAppDx trial

06/03/2021 | 12:47am EDT

View printer-friendly version

Brisbane, Australia, 3 June 2021 - ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today provides an update on Medgate AG's ('Medgate') pilot trial of ResApp's smartphone-based acute respiratory diagnostic test ResAppDx across its telemedicine services.

Medgate commenced a pilot trial of ResApp's smartphone-based acute respiratory diagnostic test ResAppDx across its telemedicine services in March 2021 (refer ASX announcement: 4 March 2021).

Following an interim review, Medgate and ResApp have decided to extend the pilot by two months. This additional time will be used to collect further data and optimise Medgate's integration of ResAppDx within its telemedicine services.

CEO and Managing Director, Dr Tony Keating said: 'Medgate and our clinical experts have found the data collected during the initial pilot period was consistent with the data from our extensive clinical studies, further demonstrating the accuracy of our cough-based diagnostic technology. We also continue our negotiations with Medgate for the commercial deployment of ResAppDx.

'Medgate has made a strong commitment to ResApp and both parties remain confident of a successful outcome. We are very appreciative of the ongoing support and insights provided by the team at Medgate and look forward to a continued innovative and mutually beneficial relationship.'

Dr Andy Fischer, CEO Medgate said: ''Our preliminary data is consistent with ResApp's clinical study results and we received positive feedback from our patients regarding their experience with the ResAppDx test. We are extending the pilot to gain more experience and further optimise our workflows to maximise the benefits of ResAppDx for Medgate and its patients.''


About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

About Medgate AG
Medgate brings the physician to where he or she is needed by patients and relies on Digital Health solutions to do so. The focus is on the well-being of the patient and the benefits to society. Medgate was founded in Switzerland in 1999 and today employs over 510 people worldwide. Since 2000, Medgate has been operating the largest medical telemedicine center in Europe and thus has an extraordinary amount of experience and knowledge in telemedicine. Medgate is also present in Germany, the Philippines and the United Arab Emirates. www.medgate.care


ResApp Health Limited published this content on 03 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 June 2021 04:46:03 UTC.

ę Publicnow 2021
09/19RESAPP HEALTH : Recruits First Patients in India in COVID-19-Related Cough Sounds Study
09/19RESAPP HEALTH : First patients recruited in COVID-19 clinical study in India
09/19Resapp Health Limited Announces First Patients Recruited in Covid-19 Clinical Study in ..
09/14RESAPP HEALTH : Gets Regulatory Nod for R&D Rebate; Shares Fall 6%
09/13RESAPP HEALTH : receives Advanced and Overseas R&D finding
09/13ResApp Health Limited Receives Advanced and Overseas R&D Finding
09/01RESAPP HEALTH : Secures Indonesian Regulatory Approval for Diagnostic App
08/31RESAPP HEALTH : ResAppDx receives regulatory approval in Indonesia
08/31ResApp Health Limited Receives Regulatory Approval in Indonesia
08/26ResApp Health Limited Reports Earnings Results for the Full Year Ended June 30, 2021
More news
Sales 2021 0,07  0,05  0,05 
Net income 2021 -6,77 M -4,93 M -4,93 M
Net cash 2021 6,40 M 4,65 M 4,65 M
P/E ratio 2021 -4,71x
Yield 2021 -
Capitalization 64,4 M 46,9 M 46,9 M
EV / Sales 2020 -
EV / Sales 2021 413 455 192x
Nbr of Employees 500
Free-Float 84,4%
Duration : Period :
ResApp Health Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESAPP HEALTH LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Managers and Directors
Tony Keating Chief Executive Officer, Executive Director & MD
Al Rey Lunar Vice President-Finance
Roger Aston Non-Executive Chairman
Christopher Ntoumenopoulos Non-Executive Director
Brian Leedman Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SNAP INC.59.94%132 215
ANGI INC.-1.17%7 260
GRUBHUB INC.-19.36%5 591
PERFECT WORLD CO., LTD.-47.59%4 958